We chose the MN1 oncogene to enhance the engraftment of CMML cells as MN1 enhances self-renewal and blocks differentiation of CD34+ cord blood cells in vitro and induces a myeloproliferative disease, but not AML, in vivo. The gene discussed is CD34; the disease is myeloproliferative disorder.